Search results
Showing 91 to 105 of 407 results for heart failure
Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Evidence-based recommendations on telemetric adjustable pulmonary artery banding for reducing pulmonary hypertension in infants with congenital heart defects. This involves placing a remote-controlled band around the pulmonary artery that can be tightened or loosened to control blood flow.
into efficacy of extracorporeal membrane oxygenation (ECMO) for acute heart failure. This should include clear documentation of patient...
evidence on cardiac contractility modulation device implantation for heart failure raises no major safety concerns. However, the...
This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.
View quality statements for QS99Show all sections
Sections for QS99
- Quality statements
- Quality statement 1: Assessment of left ventricular function
- Quality statement 2: Referral for cardiac rehabilitation
- Quality statement 3: Communication with primary care
- Quality statement 4: Cardiac rehabilitation – assessment appointment
- Quality statement 5 (developmental): Options for cardiac rehabilitation
- Update information
- About this quality standard
Evidence-based recommendations on percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve. This involves passing a closure device through a catheter to block the area that is leaking.
View recommendations for HTG585Show all sections
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
Totally endoscopic robotically assisted coronary artery bypass grafting (HTG77)
Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB). This involves using small, remote-controlled robotic arms to carry out the grafting procedure.
View recommendations for HTG77Show all sections
Sections for HTG77
Evidence-based recommendations on percutaneous mitral valve annuloplasty. This involves inserting a catheter into a large vein in the groin or neck and passing through to the heart. A device is placed into a large vein that sits next to the mitral valve to constrict the valve, with the aim of making it close properly.
View recommendations for HTG225Show all sections
Sections for HTG225
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Transient loss of consciousness ('blackouts') in over 16s (QS71)
This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.
View quality statements for QS71Show all sections
Sections for QS71
- Quality statements
- Quality statement 1: Initial assessment – recording the event, clinical history and physical examination
- Quality statement 2: Initial assessment – 12-lead electrocardiogram (ECG)
- Quality statement 3: Urgent specialist cardiovascular assessment within 24 hours of the initial assessment
- Quality statement 4: Initial assessment – unnecessary use of electroencephalogram (EEG)
- Quality statement 5: Driving advice
- Quality statement 6: Specialist cardiovascular investigation – ambulatory electrocardiogram (ECG)
- Update information
Evidence-based recommendations on off-pump coronary artery bypass grafting. This involves attaching a healthy blood vessel to the heart muscle so that blood can get round (‘bypass’) the affected part of the coronary artery.
View recommendations for HTG249Show all sections
Sections for HTG249
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Palliative care for adults: strong opioids for pain relief (CG140)
This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by NICE's guideline on care of dying adults in the last days of life .
Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)
Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.
View recommendations for HTG213Show all sections
Sections for HTG213